Literature DB >> 26158169

STAT3 activation mediates epithelial-to-mesenchymal transition in human hepatocellular carcinoma cells.

Chuan-hai Zhang, Feng-Lin Guo, Ge-Liang Xu, Wei-Dong Jia, Yong-Sheng Ge.   

Abstract

BACKGROUND/AIMS: Epithelial-to-mesenchymal transition (EMT) is critical for the development of the invasion and metastasis in human cancers. Recently, signal transducer and activator of transcription 3 (STAT3) activation has been linked to EMT program in breast cancer. However, the actual association of STAT3 activation with EMT, and its mediated tumor invasion and metastasis remains elusive in hepatocellular carcinoma (HCC). The aim of this study was to investigate the correlation between STAT3 activation and EMT, as well as the underlying mechanism involved in HCC progression.
METHODOLOGY: We treated SMMC-7721 cells with a known STAT3 activator, epithelial growth factor (EGF); in the absence or presence of JSI-124, a selective STAT3 inhibitor. The EMT-associated morphologic and molecular changes of cells were analyzed. The EMT-mediated HCC cell invasion, migration and adhesion were evaluated.
RESULTS: In this study, we found that STAT3 activation induced by EGF was associated significantly with morphologic changes, cytoskeleton rearrangement and molecular changes consistent with EMT in SMMC-7721 cells; STAT3 activation-mediated EMT may be transcriptionally induced by Twist. STAT3 activation-mediated EMT also promoted HCC cell invasion, migration and adhesion significantly.
CONCLUSIONS: In summary, our study show for the first time that STAT3 activation may induce invasion and metastasis through the mediation of EMT in HCC cells. Activated STAT3 and EMT markers can serve as molecular targets for HCC treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 26158169

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  9 in total

1.  Detection of promoter methylation status of suppressor of cytokine signaling 3 (SOCS3) in tissue and plasma from Chinese patients with different hepatic diseases.

Authors:  Ling Wei; Yuan Huang; Rongce Zhao; Jing Zhang; Qiuying Liu; Weibo Liang; Xueqin Ding; Bo Gao; Bo Li; Chengjun Sun; Jingyang He; Xiaoqin Yu; Zhongjian Liu; Aimin Sun; Yang Qin
Journal:  Clin Exp Med       Date:  2017-09-26       Impact factor: 3.984

2.  Protrusion-localized STAT3 mRNA promotes metastasis of highly metastatic hepatocellular carcinoma cells in vitro.

Authors:  Yan-Hong Liu; Jia-Lu Jin; Yu-Zhe Wang; Ying Tan; Ying-Ying Zhou; Ting Peng; Feng Li; Wan-Dong Liang; Pascal Chartrand; Yu-Yang Jiang; Zhi-Fa Shen
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

Review 3.  Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies.

Authors:  Bruno Sainz; Emily Carron; Mireia Vallespinós; Heather L Machado
Journal:  Mediators Inflamm       Date:  2016-02-14       Impact factor: 4.711

Review 4.  Relationship between epithelial-to-mesenchymal transition and the inflammatory microenvironment of hepatocellular carcinoma.

Authors:  Long Yan; Feng Xu; Chao-Liu Dai
Journal:  J Exp Clin Cancer Res       Date:  2018-08-29

5.  Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells.

Authors:  María José López-Grueso; Raúl González; Jordi Muntané; José Antonio Bárcena; C Alicia Padilla
Journal:  Antioxidants (Basel)       Date:  2019-10-22

Review 6.  STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma.

Authors:  Carol Lee; Siu Tim Cheung
Journal:  Cancers (Basel)       Date:  2019-10-25       Impact factor: 6.639

7.  The PKM2 activator TEPP-46 suppresses kidney fibrosis via inhibition of the EMT program and aberrant glycolysis associated with suppression of HIF-1α accumulation.

Authors:  Haijie Liu; Yuta Takagaki; Asako Kumagai; Keizo Kanasaki; Daisuke Koya
Journal:  J Diabetes Investig       Date:  2020-12-31       Impact factor: 4.232

8.  miR-655 suppresses epithelial-to-mesenchymal transition by targeting Prrx1 in triple-negative breast cancer.

Authors:  Zhi-Dong Lv; Bin Kong; Xiang-Ping Liu; Li-Ying Jin; Qian Dong; Fu-Nian Li; Hai-Bo Wang
Journal:  J Cell Mol Med       Date:  2016-01-28       Impact factor: 5.310

9.  Quercetin inhibits epithelial-mesenchymal transition, decreases invasiveness and metastasis, and reverses IL-6 induced epithelial-mesenchymal transition, expression of MMP by inhibiting STAT3 signaling in pancreatic cancer cells.

Authors:  Dinglai Yu; Tingting Ye; Yukai Xiang; Zhehao Shi; Jie Zhang; Bin Lou; Fan Zhang; Bicheng Chen; Mengtao Zhou
Journal:  Onco Targets Ther       Date:  2017-09-25       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.